Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis
Clinical Rheumatology - United Kingdom
doi 10.1007/s10067-019-04679-y
Full Text
Open PDFAbstract
Available in full text
Date
August 8, 2019
Authors
Publisher
Springer Science and Business Media LLC